Table 1. Baseline characteristics and sPLA2-IIa concentrations and activities in patients with stable coronary heart disease.

				sPLA2-IIa concentration (ng/mL)		sPLA2-IIa activity (nmol/mL/min)
Participant characteristic		N	%	Median	Inter-quartile range	Median	Inter-quartile range
Overall populationa		1012	100	2.50	1.45–4.86	1.21	0.93–1.58
Age at baseline	30–39 years	20	2	1.47	0.92–1.91	0.95	0.76–1.22
	40–49 years	125	12	1.71	1.10–3.51	1.07	0.89–1.41
	50–59 years	292	29	2.08	1.31–3.91	1.12	0.87–1.44
	60–70 years	575	57	2.99	1.71–5.63	1.30	0.97–1.70
Sex	Female	152	15	4.99	2.20–8.21	1.53	1.17–2.15
	Male	860	85	2.33	1.39–4.20	1.16	0.91–1.51
Patient group	Acute coronary syndrome	127	13	2.00	1.26–3.81	1.11	0.93–1.39
	Coronary intervention	296	29	2.77	1.69–5.36	1.25	0.94–1.68
	Myocardial infarction	589	58	2.48	1.40–4.68	1.21	0.92–1.57
Body mass index	≤25 kg/m2	285	28	2.47	1.44–4.99	1.16	0.92–1.53
	>25–30 kg/m2	569	56	2.41	1.44–4.61	1.21	0.91–1.55
	>30 kg/m2	157	16	3.14	1.49–5.98	1.35	1.01–1.79
Disease history	Diabetes mellitus	177	18	3.45	1.80–6.26	1.35	1.05–1.76
	Hypertension	564	56	2.77	1.54–5.47	1.26	0.94–1.67
Discharge prescriptions	ACE-inhibitor	535	53	2.63	1.46–4.81	1.22	0.90–1.60
	Lipid-lowering drugs	780	77	2.33	1.41–4.47	1.19	0.92–1.53
Smoking history	Never	316	31	2.51	1.48–5.49	1.24	0.94–1.66
	Formerly	645	64	2.48	1.42–4.63	1.20	0.92–1.56
	Currently	51	5	2.66	1.73–5.09	1.16	0.95–1.41

^aN and percentages refer to the subjects with concentration measurements available. Activity measurements were missing for 22 of these.